Mohammed Aleskandarany MD, PhD
Mohammed Aleskandarany MD, PhD
Senior Lecturer of Pathology, University of Derby, UK
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes
EA Rakha, SE Elsheikh, MA Aleskandarany, HO Habashi, AR Green, ...
Clinical Cancer Research 15 (7), 2302-2310, 2009
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen
HO Habashy, DG Powe, CM Staka, EA Rakha, G Ball, AR Green, ...
Breast cancer research and treatment 119, 283-293, 2010
CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome
S Elsheikh, AR Green, MA Aleskandarany, M Grainge, CE Paish, ...
Breast cancer research and treatment 109, 325-335, 2008
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
MA Aleskandarany, AR Green, AA Benhasouna, FF Barros, K Neal, ...
Breast Cancer Research 14, 1-11, 2012
MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
MA Aleskandarany, EA Rakha, RD Macmillan, DG Powe, IO Ellis, ...
Breast cancer research and treatment 127, 591-599, 2011
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
AR Green, MA Aleskandarany, D Agarwal, S Elsheikh, CC Nolan, ...
British journal of cancer 114 (8), 917-928, 2016
A CD44/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer
MAH Ahmed, MA Aleskandarany, EA Rakha, RZA Moustafa, ...
Breast cancer research and treatment 133, 979-995, 2012
The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast
EA Rakha, M Aleskandarany, ME El-Sayed, RW Blamey, CW Elston, ...
European Journal of Cancer 45 (10), 1780-1787, 2009
PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis
MA Aleskandarany, EA Rakha, MAH Ahmed, DG Powe, EC Paish, ...
Breast cancer research and treatment 122, 45-53, 2010
Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis
MA Aleskandarany, R Abduljabbar, I Ashankyty, A Elmouna, D Jerjees, ...
Breast cancer research and treatment 159, 215-227, 2016
Tumour heterogeneity of breast cancer: from morphology to personalised medicine
MA Aleskandarany, ME Vandenberghe, C Marchiò, IO Ellis, A Sapino, ...
Pathobiology 85 (1-2), 23-34, 2018
Human helicase RECQL4 drives cisplatin resistance in gastric cancer by activating an AKT–YB1–MDR1 signaling pathway
D Mo, H Fang, K Niu, J Liu, M Wu, S Li, T Zhu, MA Aleskandarany, A Arora, ...
Cancer Research 76 (10), 3057-3066, 2016
MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer
ML Craze, H Cheung, N Jewa, NDM Coimbra, D Soria, R El-Ansari, ...
British journal of cancer 118 (2), 258-265, 2018
FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer
HO Habashy, EA Rakha, M Aleskandarany, MAH Ahmed, AR Green, ...
Breast cancer research and treatment 129, 11-21, 2011
Heterogeneity of tumour‐infiltrating lymphocytes in breast cancer and its prognostic significance
M Althobiti, MA Aleskandarany, C Joseph, M Toss, N Mongan, ...
Histopathology 73 (6), 887-896, 2018
Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer
A Albasri, S Al-Ghamdi, W Fadhil, M Aleskandarany, YC Liao, D Jackson, ...
Oncogene 30 (26), 2997-3002, 2011
Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study
MA Aleskandarany, OH Negm, AR Green, MAH Ahmed, CC Nolan, ...
Breast cancer research and treatment 145, 339-348, 2014
Molecular mechanisms underlying lymphovascular invasion in invasive breast cancer
MA Aleskandarany, SN Sonbul, A Mukherjee, EA Rakha
Pathobiology 82 (3-4), 113-123, 2015
Breast cancer intratumour heterogeneity: current status and clinical implications
C Joseph, A Papadaki, M Althobiti, M Alsaleem, MA Aleskandarany, ...
Histopathology 73 (5), 717-731, 2018
Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer
MA Aleskandarany, EA Rakha, MA Ahmed, DG Powe, IO Ellis, AR Green
Breast cancer research and treatment 127, 407-416, 2011
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20